Anti-retroviral Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Anti-retroviral Drug Market is Segmented by Drug Class (Protease Inhibitors, Integrase Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), and Other Drug Class) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Anti-Retroviral Drugs Market Size

Anti-retroviral Drugs Market Summary

Anti-Retroviral Drugs Market Analysis

The Anti-retroviral Drugs Market is expected to register a CAGR of 4% during the forecast period.

The COVID-19 pandemic impacted the growth of the anti-retroviral drug market. For instance, an article published by the journal GHSP in December 2021 reported that initially, some of the antiretroviral drugs were largely used for the treatment of COVID-19 and the rising COVID-19 infections surged the demand for these drugs. Thus, increasing COVID-19 cases led to increasing demand for antiretroviral drugs. However, in the current scenario, it is anticipated that a substantial decrease in COVID-19 cases due to the increased vaccination and availability of other drugs for COVID-19 treatment, and the studied market has lost some traction that was gained during the pandemic. However, the studied market is expected to have favorable growth due to the presence of other retrovirus infections over the forecast period of the study.

The factors driving the growth of the studied market are the rising burden of HIV, increasing investment in R&D, and an increase in the availability of novel drugs with better efficacy. For instance, in 2022, India's HIV Estimates Factsheet reported that the annual new infection (ANI) of HIV is estimated at 62.97 thousand in 2021 in India. Similarly, in July 2022 WHO reported that 38.4 million people are living with HIV in the year 2021. WHO also reported that the African region remains most severely affected, with nearly 1 in every 25 adults (3.4%) living with HIV and accounting for more than two-thirds of the people living with HIV worldwide. Also, according to WHO, HIV cases got significantly increased by 32.8% in the last two decades. Thus, rising cases of HIV are increasing the demand for antiretroviral drugs.

Also, the increased R&D expenses by various pharmaceutical companies are driving the growth of the studied market. For instance, in June 2022, GSK reported an investment of EUR 1 billion to accelerate R&D activities for the treatment of infectious diseases that disproportionately impact lower-income countries. The company reported that this research will focus on new and disruptive vaccines and medicines to prevent and treat HIV (through ViiV Healthcare), malaria, tuberculosis, and other infectious diseases, accounting for more than 60% of the disease burden in many lower-income countries. The news also reported that GSK Global Health R&D Hubs are progressing with more than 30 potential new vaccines and medicines, targeting 13 high-burden infectious diseases, including anti-retroviral drug infection. Thus, the increasing R&D expenses are driving the growth of the studied market.

Furthermore, the increasing availability of novel drugs for HIV treatment is driving the growth of the studied market. For instance, in June 2022, Gilead resubmiited new drug application for lenacapavir to the USFDA as a treatment for MDR HIV, lenacapavir is still only in phase 2 studies for treatment. Similarly, in March 2021, Gilead and MSD entered into a new partnership for developing long-acting formulations for the fight against HIV infections. Thus, such development of novel drugs and strategic collaboration between key market players are driving the growth of the studied market.

Thus, the rising burden of HIV, increasing investment in R&D, and availability of novel drugs with better efficacy contributes to the significant growth of the market. However, the side effects of drugs may slow down the growth of the study over the forecast period.

Anti-Retroviral Drugs Industry Overview

The anti-retroviral market is fragmented due to many companies operating globally and regionally. The competitive landscape includes an analysis of a few international, as well as local companies which hold the market shares and are well-known, are AbbVie Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Merck & Co, Inc., Viatris Inc. (Mylan Inc.), GlaxoSmithKline plc (ViiV Healthcare), Cipla Inc., Johnson and Johnson, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.

Anti-Retroviral Drugs Market Leaders

  1. Boehringer Ingelheim International GmbH

  2. Bristol-Myers Squibb Company

  3. Gilead Sciences, Inc.

  4. Merck & Co, Inc.

  5. GlaxoSmithKline plc (ViiV Healthcare)

  6. *Disclaimer: Major Players sorted in no particular order
Anti-retroviral Drugs Market  Concentration
Need More Details on Market Players and Competiters?
Download PDF

Anti-Retroviral Drugs Market News

  • In September 2022, Merck reported initiating a new phase 3 clinical trial evaluating once-daily oral islatravir for HIV-1 infection.
  • In August 2022, Gilead received the global regulatory approval of Sunlenca (Lenacapavir), the twice-yearly HIV treatment option.

Anti-Retroviral Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of HIV
    • 4.2.2 Increasing Investment in R&D
    • 4.2.3 Increase in Availability of Novel Drugs with Better Efficacy
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Drug Class
    • 5.1.1 Protease Inhibitors
    • 5.1.2 Integrase Inhibitors
    • 5.1.3 Multi-class Combination Products
    • 5.1.4 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • 5.1.5 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 5.1.6 Other Drug Class
  • 5.2 Geography
    • 5.2.1 North America
    • 5.2.1.1 United States
    • 5.2.1.2 Canada
    • 5.2.1.3 Mexico
    • 5.2.2 Europe
    • 5.2.2.1 Germany
    • 5.2.2.2 United Kingdom
    • 5.2.2.3 France
    • 5.2.2.4 Italy
    • 5.2.2.5 Spain
    • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
    • 5.2.3.1 China
    • 5.2.3.2 Japan
    • 5.2.3.3 India
    • 5.2.3.4 Australia
    • 5.2.3.5 South Korea
    • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
    • 5.2.4.1 GCC
    • 5.2.4.2 South Africa
    • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
    • 5.2.5.1 Brazil
    • 5.2.5.2 Argentina
    • 5.2.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Boehringer Ingelheim International GmbH
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 F. Hoffmann-La Roche Ltd
    • 6.1.5 Gilead Sciences, Inc.
    • 6.1.6 Merck & Co, Inc.
    • 6.1.7 Viatris Inc. (Mylan Inc.)
    • 6.1.8 GlaxoSmithKline plc (ViiV Healthcare)
    • 6.1.9 Cipla Inc.
    • 6.1.10 Johnson and Johnson
    • 6.1.11 Pfizer Inc.
    • 6.1.12 Teva Pharmaceutical Industries Ltd.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Anti-Retroviral Drugs Industry Segmentation

As per the scope of the report, anti-retroviral drugs are medications for treating infection by retroviruses, primarily HIV. A retrovirus is a group of viruses that belongs to the family Retroviridae, and they characteristically carry their genetic blueprint in the form of ribonucleic acid (RNA). The anti-retroviral drugs hinder the multiplication of these viruses rather than killing them. The Anti-Retroviral Drug Market is Segmented by Drug Class (Protease Inhibitors, Integrase Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), and Other Drug Class) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Drug Class Protease Inhibitors
Integrase Inhibitors
Multi-class Combination Products
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Other Drug Class
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Anti-Retroviral Drugs Market Research FAQs

What is the current Anti-retroviral Drugs Market size?

The Anti-retroviral Drugs Market is projected to register a CAGR of 4.0% during the forecast period (2025-2030)

Who are the key players in Anti-retroviral Drugs Market?

Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Merck & Co, Inc. and GlaxoSmithKline plc (ViiV Healthcare) are the major companies operating in the Anti-retroviral Drugs Market.

Which is the fastest growing region in Anti-retroviral Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Anti-retroviral Drugs Market?

In 2025, the North America accounts for the largest market share in Anti-retroviral Drugs Market.

What years does this Anti-retroviral Drugs Market cover?

The report covers the Anti-retroviral Drugs Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Anti-retroviral Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Anti-retroviral Drugs Industry Report

Statistics for the 2025 Anti-retroviral Drugs market share, size and revenue growth rate, created by Mordor Intelligenceā„¢ Industry Reports. Anti-retroviral Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Anti-retroviral Drugs Report Snapshots

Compare market size and growth of Anti-retroviral Drugs Market with other markets in Healthcare Industry

Anti-retroviral Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)